> HDMA Testifies
      Supporting HR5839

> HDMA Applauds
      Introduction of
      HR 5839

> HDMA Applauds
      NCPA, FBI LEEDA and
      Purdue Pharma

> HDMA Commends
      California Board of
      Pharmacy Decision

> New Data Management
      & Sharing Research
      Now Available!


print page

 

 

 

HDMA Anti-Trust Policy

It is the unqualified policy of HDMA and all of its operating committees to conduct their operations in strict compliance with the antitrust laws of the United States.

HDMA’s antitrust policy prohibits any discussions which constitute or imply an agreement or understanding concerning:  1) prices, discounts, or terms or conditions of sale; 2) profits, or profit margins or cost data; 3) market shares, sales territories or markets; 4) allocation of customers or territories; 5) selection, rejection or termination of customers or suppliers; 6) restricting the territory or markets in which a company may resell products; 7) restricting the customers to whom a company may sell; or 8) any matter which is inconsistent with the proposition that each member company of HDMA must exercise its independent business judgment in pricing its services or products, dealing with its customers and suppliers and choosing the markets in which it will compete. 

HDMA membership, Board of Directors and committee meetings shall be conducted pursuant to agendas distributed in advance to attendees; discussions shall be limited to agenda items which have been reviewed by HDMA legal counsel; there shall be no substantive discussions of HDMA matters other than at official meetings; and minutes shall be distributed to attendees promptly upon review by HDMA legal counsel. 

 
© Copyright Healthcare Distribution Management Association.
All rights reserved.
HDMA: M | C | D